Zoetis Inc. (NYSE:ZTS) Receives Consensus Rating of “Buy” from Brokerages

Zoetis Inc. (NYSE:ZTS) has received an average recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $217.11.

Several brokerages have issued reports on ZTS. Stifel Nicolaus reaffirmed a “buy” rating and set a $200.00 price target on shares of Zoetis in a research note on Tuesday, August 27th. BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th.

Zoetis Stock Up 0.8 %

ZTS stock opened at $195.74 on Wednesday. The company’s 50 day moving average is $183.65 and its 200 day moving average is $174.15. The stock has a market cap of $88.68 billion, a price-to-earnings ratio of 37.71, a price-to-earnings-growth ratio of 2.92 and a beta of 0.88. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis has a 1-year low of $144.80 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same quarter in the prior year, the firm earned $1.41 EPS. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. Sell-side analysts predict that Zoetis will post 5.84 EPS for the current fiscal year.

Institutional Trading of Zoetis

Institutional investors have recently made changes to their positions in the stock. SS&H Financial Advisors Inc. boosted its position in Zoetis by 15.4% during the 2nd quarter. SS&H Financial Advisors Inc. now owns 6,118 shares of the company’s stock valued at $1,061,000 after buying an additional 818 shares during the period. Heritage Wealth Management Inc. bought a new position in shares of Zoetis during the second quarter valued at about $624,000. Sanctuary Advisors LLC purchased a new stake in shares of Zoetis during the second quarter worth about $19,525,000. Clear Rock Advisors LLC grew its stake in shares of Zoetis by 8.7% in the second quarter. Clear Rock Advisors LLC now owns 16,427 shares of the company’s stock worth $2,848,000 after purchasing an additional 1,314 shares during the last quarter. Finally, Clearbridge Investments LLC increased its holdings in Zoetis by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after purchasing an additional 166,517 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.